Our Mission

Seinda Corporation aims to bring excellence and precision to ophthalmology by providing improved diagnostic and therapeutic choices for eye care. We focus on integrating innovative technologies into ophthalmic diagnosis and treatment to improve patient outcomes.

Overview

With deep scientific roots and a commitment to precision medicine, Seinda was founded to redefine ocular health.

Today, we are a VC-backed innovation company with a global footprint. We have successfully launched multiple diagnostic solutions and are advancing our lead therapeutic candidate through late-stage clinical trials. Seinda is shaping the future of ophthalmic care—delivering science-driven solutions with global reach.

Picture3
Picture1
Picture4
Picture5

Vision

Bringing precision medicine to eye care to improve quality of vision and ocular health.

Core Team Members

Jing-Feng Huang, Ph.D.

Founder and CEO

View Bio

Jean Marc Terral

VP of International Business Development & Market Expansion

View Bio

Frank Chen

US Strategy Advisor

View Bio

Yeqing Liu

VP of POCT Marketing

View Bio

Adam An

VP of Corporate Operations

View Bio

Advisors

Zuguo Liu, MD PH.D.

Clinical and Medical Advisor

View Bio

Gary D. Novack, Ph.D.

US Regulatory Advisor

View Bio

Strategy

Data-Driven Insight, Purposeful Innovation

At Seinda, strategy starts with science. Our extensive biomarker database deepens our understanding of ocular disease mechanisms—guiding every decision from diagnostics to drug development.
This informed, targeted approach is not just how we work—it’s why we create real, differentiated value in ophthalmic care.

Partners

We are always seeking strategic partners for regional and/or global commercialization of our products. For more information, please email us info@seindabio.com.

Linkedin
Linkedin Facebook-f

Jing-Feng Huang, Ph.D.

Founder and CEO

Dr. Huang founded Seinda in 2015 with the vision of integrating immunology and biomarker research in ophthalmic diseases and developing innovative point-of-care (POC) in vitro diagnostic tests for eye disorders. She has accumulated extensive knowledge from her research in T cell regulation and pathological mechanism of immune diseases, and has published 30 research articles in leading journals, including Science, J. Clin. Inv., J Exp. Med, PNAS, Blood, Ophthalmology, IOVS. As an expert in ophthalmological biomarkers and pathological mechanism research, Dr. Huang is well-recognized internationally by experts in these fields.

With nearly 20 years of experience in innovative drug R&D and clinical development of multinational pharmaceutical companies, Dr. Huang has been engaged in the research and development of new drugs in the United States for more than ten years at Johnson & Johnson (J&J), for immune diseases such as lupus erythematosus, psoriasis, rheumatoid arthritis, asthma and allergies. Later, she joined Pfizer as Director of the Global Ophthalmic Clinical Development Department, during which she led multiple dry eye clinical trials and translational medicine research. From 2013 to 2017, Dr. Huang served as a special expert consultant of the National Eye Institute (NEI) to guide the plan design, implementation supervision, data analysis and report writing of a large multi-center dry eye clinical trial in the United States. Related dry eye clinical trial research results were published in the New England Journal of Medicine (NEJM). Under Dr. Huang’s leadership, Seinda has developed a dry eye diagnostic reagent and conducted over 1,100 multi-center clinical trials throughout China. This reagent is now at commercial stage, with more rapid diagnostic products for ophthalmic diseases that fill the need for ophthalmic in vitro testing products soon to follow. Dr. Huang obtained her PhD at The Scripps Research Institute (TSRI) in La Jolla, California and conducted her post-doctoral research in Immunology and Bioinformatics at J&J Pharmaceutical Research Institute.

Linkedin Facebook-f

Jean Marc Terral

VP of International Business Development & Market Expansion

A dynamic business executive and transformation leader with an international career spanning General Management, Sales, and Marketing in the Life Sciences Industry. Known for his ability to drive change, he specializes in taking organizations to the next level—turning chaos into order, inefficiency into productivity, and disengagement into high performance. With 20 years of experience in large, multibillion-dollar multinational corporations, Jean-Marc developed expertise in business transformation, strategic growth, and merger integration. His leadership has helped organizations navigate complex challenges, streamline operations, and accelerate revenue growth. Today, Jean-Marc focuses on critical management, strategy, and growth challenges. He provides hands-on guidance to build scalable, results-driven sales organizations that achieve long-term success.

Linkedin Facebook-f

Frank Chen

US Strategy Advisor

Frank Chen is a seasoned executive with extensive leadership experience in medical devices, pharmaceuticals, and biotechnology, with a strong focus on operations, investment strategy, and global team management. As President of Santen Venture Investments from 2015 to 2023, he led strategic investments in best-in-class ophthalmic technologies, advancing innovation through the corporate venture arm of Santen Pharmaceuticals. Known for driving data-informed initiatives and organizational growth, he excels in fast-paced, innovation-driven environments. Frank holds an MBA from the University of Southern California’s Marshall School of Business.

Linkedin Facebook-f

Yeqing Liu

VP of POCT Marketing

Yeqing Liu is a veteran sales and marketing executive in the biopharmaceutical industry, with nearly 20 years of leadership experience across biotechnology, pharmaceutical sales, channel management, and medical services. His career spans Fortune Global 500 multinationals, state-owned enterprises, and private companies, where he has built and led high-performing teams across diverse business environments. Yeqing holds a Master of Science in Molecular Genetics from Jinan University and a Master of Science in Applied Psychology from Sun Yat-sen University, bringing both scientific and strategic insight to commercial execution.

Linkedin Facebook-f

Adam An

VP of Corporate Operations

With 19 years of progressive experience in human resources and operations management, Adam is a strategic HR leader with a strong track record in driving organizational transformation, implementing robust HR systems, and developing high-impact talent strategies. As a former Senior HR Director at a publicly listed medical group, he successfully led multiple enterprise-wide initiatives that aligned people strategy with business goals. Adam holds an MBA from Hong Kong Baptist University and brings deep expertise in navigating complex, fast-paced environments with a focus on sustainable growth and operational excellence.

Linkedin Facebook-f

Zuguo Liu, MD PH.D.

Clinical and Medical Advisor

TFOS DEWS Ⅱ Steering Committee Member

President,Asia Dry Eye Society

Founder and President,China Dry Eye Society

Cornea Director,Xiamen Eye Center,China

Founder and Dean of Ophthalmology Research Institute,Xiamen University,China

Linkedin Facebook-f

Gary D. Novack, Ph.D.

US Regulatory Advisor

Board certified clinical pharmacologist and medical writer.

30+ years experience in pharmaceutical research and development, ranging from the laboratory to the marketplace.

Author of over 200 full publications in clinical pharmacology, ophthalmology, dermatology and neurosciences.

Professor of Pharmacology and Ophthalmology at the School of Medicine at University of California, Davis